- Home
- TPG vs MDGL Comparison
TPG vs MDGL Comparison
Compare TPG & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPG
- MDGL
- Stock Information
- Founded
- TPG 1992
- MDGL 2011
- Country
- TPG United States
- MDGL United States
- Employees
- TPG N/A
- MDGL N/A
- Industry
- TPG Investment Managers
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- TPG Finance
- MDGL Health Care
- Exchange
- TPG Nasdaq
- MDGL Nasdaq
- Market Cap
- TPG 8.9B
- MDGL 9.6B
- IPO Year
- TPG 2022
- MDGL N/A
- Fundamental
- Price
- TPG $57.66
- MDGL $587.32
- Analyst Decision
- TPG Buy
- MDGL Strong Buy
- Analyst Count
- TPG 13
- MDGL 13
- Target Price
- TPG $65.33
- MDGL $543.33
- AVG Volume (30 Days)
- TPG 2.2M
- MDGL 470.4K
- Earning Date
- TPG 11-04-2025
- MDGL 11-04-2025
- Dividend Yield
- TPG 3.02%
- MDGL N/A
- EPS Growth
- TPG N/A
- MDGL N/A
- EPS
- TPG 0.10
- MDGL N/A
- Revenue
- TPG $4,255,344,000.00
- MDGL $740,640,000.00
- Revenue This Year
- TPG N/A
- MDGL $395.75
- Revenue Next Year
- TPG $24.79
- MDGL $65.73
- P/E Ratio
- TPG $591.85
- MDGL N/A
- Revenue Growth
- TPG 24.91
- MDGL 864.21
- 52 Week Low
- TPG $37.52
- MDGL $265.00
- 52 Week High
- TPG $72.98
- MDGL $594.99
- Technical
- Relative Strength Index (RSI)
- TPG 55.81
- MDGL 74.69
- Support Level
- TPG $54.09
- MDGL $535.00
- Resistance Level
- TPG $57.20
- MDGL $594.99
- Average True Range (ATR)
- TPG 1.96
- MDGL 28.63
- MACD
- TPG 0.18
- MDGL 6.39
- Stochastic Oscillator
- TPG 75.18
- MDGL 93.69
About TPG TPG Inc.
TPG Inc is an alternative asset management firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, Market Solutions, and TPG Angelo Gordon. The company focuses on large-scale, control-oriented private equity investments.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.